Biosplice Therapeutics Overview

  • Founded

  • 2008

Founded
  • Status

  • Private

  • Employees

  • 74

Employees
  • Latest Deal Type

  • PE Growth

  • Financing Rounds

  • 10

Biosplice Therapeutics General Information

Description

Operator of a tissue-level therapeutic drugs company focused on osteoarthritis and oncology, with early-stage programs in neurology and other areas of significant unmet medical need. The company discovers new targets and biological processes in the Wnt pathway, allowing them to develop small molecule drugs that potentially address numerous degenerative conditions, thereby leading to the discovery of new, potentially curative therapies for certain diseases.

Contact Information

Website
www.biosplice.com
Formerly Known As
Wintherix & Epitherix, Samumed
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Drug Discovery
Primary Office
  • 9360 Towne Centre Drive
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Biosplice Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biosplice Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biosplice Therapeutics‘s full profile, request access.

Request a free trial

Biosplice Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a tissue-level therapeutic drugs company focused on osteoarthritis and oncology, with early-stage programs i
Drug Discovery
San Diego, CA
74 As of 2023
00000
0000000 0000 00000

000000

equat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dol
0000 000000000
San Diego, CA
0 As of 0000
000.00
000000000 000.00

000000

t esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
0000 000000000
Jersey City, NJ
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biosplice Therapeutics Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Histogen Formerly VC-backed San Diego, CA 0 000.00 000000000 000.00
00000000 Formerly VC-backed Jersey City, NJ 00 00000 00000000 00000
0000000 0000000000 Corporate Backed or Acquired Lexington, MA 00 00000 000000&0 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 0 00000 000000&0 00000
00000000 000000000 Accelerator/Incubator Backed New York, NY 000000000000
You’re viewing 5 of 48 competitors. Get the full list »

Biosplice Therapeutics Patents

  • 418

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 48

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Biosplice Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3911317-A2 Methods of treating cartilage disorders through inhibition of clk and dyrk Inactive 17-Jan-2019 0000000000
US-20230000842-A1 Methods of treating cartilage disorders through inhibition of clk and dyrk Pending 17-Jan-2019 0000000000
EP-3813826-A1 Methods of treating cancer using a clk inhibitor Pending 26-Jun-2018 000000000
EP-3813826-A4 Methods of treating cancer using a clk inhibitor Pending 26-Jun-2018 000000000 0
US-20220062240-A1 Methods of treating cancer using a clk inhibitor Pending 26-Jun-2018 A61P35/00
To view Biosplice Therapeutics’s complete patent history, request access »

Biosplice Therapeutics Executive Team (16)

Name Title Board Seat Contact Info
Cevdet Samikoglu Chief Executive Officer & Board Member
Erich Horsley Chief Financial Officer & Chief Business Officer
Scott Bulcao Chief Legal Officer
Osman Kibar Ph.D Co-Founder & Executive Chairman
Jeymi Tambiah MD Senior Vice President of Clinical Development and External Innovation
You’re viewing 5 of 16 executive team members. Get the full list »

Biosplice Therapeutics Board Members (11)

Name Representing Role Since
000000 000000000 Biosplice Therapeutics Chief Executive Officer & Board Member 000 0000
00000000 0000000 SymBiosis Capital Management Board Observer 000 0000
00000 0000000 Self Board Member 000 0000
000000 000 00.0 Self Board Member 000 0000
000 00000000 00 aMoon Fund Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Biosplice Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biosplice Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biosplice Therapeutics‘s full profile, request access.

Request a free trial